Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ELANE | P08246 | 2/20 | 0.47 |
| ▸ | CTSK | P43235 | 3/20 | 0.46 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16829101 | 1.00 | ATM (0.53) | ATMELANECTSKPRTN3CTRB1 | |
| SCHEMBL475033 | 0.88 | ATM (0.62) | ATMELANECTSKCTRB1CTSL | |
| SCHEMBL7357546 | 0.88 | ATM (0.62) | ATMELANECTSKCTRB1CTSL | |
| SCHEMBL7329364 | 0.82 | ATM (0.57) | ATMELANECTSKPRTN3CTRB1 | |
| SCHEMBL7413984 | 0.81 | ATM (0.50) | ATMELANECTSKPRTN3CTRB1 | |
| SCHEMBL9276917 | 0.81 | FPR2 (0.50) | ATMELANECTSKCTSLCTSS | |
| SCHEMBL7407249 | 0.81 | FPR2 (0.50) | ATMELANECTSKCTSLCTSS | |
| SCHEMBL7415067 | 0.81 | ATM (0.47) | ATMELANECTSKPRTN3CTSL | |
| SCHEMBL19867876 | 0.79 | ATM (0.51) | ATMELANECTSKPRTN3CTRB1 | |
| SCHEMBL7412535 | 0.78 | ATM (0.47) | ATMELANECTSKPRTN3CTRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2019-08-15 | — | — | US | disclosed |
| US-10316039-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2019-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | ATM 4023/4885ELANE 2939/4885CTSK 4633/4885 |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | P2RX3, P2RX2, P2RX1 | ATM 4023/4885ELANE 2939/4885CTSK 4633/4885 |
| US-10316039-B2 | P2X3 and/or P2X2/3 compounds and methods | P2RX3, P2RX2, P2RX1 | ATM 4023/4885ELANE 2939/4885CTSK 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.